Abstract
We have used a focused and comprehensive ophthalmology patent database to characterize the international patenting landscape dedicated to the pharmacological treatment of cataract, corneal opacities and dystrophies, and complicated refractive errors. A total of 201 disclosures related to cataract or corneal clouding (published between 1982 and 2011), and 99 documents (published between 1991 and 2011) related to refractive or geometry errors were identified. Current applications for the treatment or prevention of primary cataract have ceased to address diabetic cataract specifically through the inhibition of glycation-specific mechanisms. The most innovative approaches for pharmacotherapy of the lens focus on phase separation inhibitors, modulators of the TGF-β pathway, and matrix metalloproteinase inhibition. Patenting for the prevention of secondary cataracts as a delayed complication of intraocular lens insertion follows similar routes. For keratoconus, progressive myopia and Avellino corneal dystrophy, the focus remains on efficiently stabilizing the corrected shape of the cornea in the course of orthokeratology treatments. We expect future patenting in the fields of our investigation to concentrate more heavily on molecular medicine, in close lockstep with biotechnology and genetic testing.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
